VASCEPA (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in…
First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses
Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, including urgent, emergent, and elective interventions
Percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) reduced by 32% and 39%, respectively, in post hoc exploratory analyses
DUBLIN, Ireland and BRIDGEWATER, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that data from the REDUCE-IT study presented by Benjamin E. Peterson, M.D., Brigham and Womens Hospital Heart & Vascular Center and Harvard Medical School, at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions, showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001).
These findings from the REDUCE-IT study put in further context the broad-reaching impact of icosapent ethyl on reducing the burden of cardiovascular disease for patients, commented Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Womens Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School, and senior author of the REDUCE-IT REVASC analyses. To the best of our knowledge, this is the first non-LDL cholesterol intervention in a major randomized trial in which analyses support that statin-treated patients underwent fewer CABG surgeries, further highlighting the substantial impact of icosapent ethyl on the underlying atherothrombotic burden in this at-risk population.
Coronary revascularization procedures are invasive, carry multiple risks, and can have significant direct and indirect costs. Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. These procedures, whether pre-scheduled or performed in an emergency, oftentimes result in additional time spent in a healthcare setting.
The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).
REDUCE-IT was not specifically powered to examine individual cardiovascular endpoints, therefore p-values presented for these revascularization analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, coronary revascularization as an endpoint can sometimes be considered subjective; however, these endpoints were adjudicated by an independent, blinded clinical endpoint committee. Results from the total coronary revascularization events analyses are consistent across the various recurrent event statistical models and are also consistent with the first coronary revascularization events results. Together, the REDUCE-IT first and total coronary revascularization events results support the robustness and consistency of the clinical benefit of VASCEPA therapy in reducing coronary revascularization.
Revascularization procedures significantly impact the healthcare system, said Steven Ketchum, Ph.D., senior vice president and president, research & development and chief scientific officer, Amarin. These data reflect new findings consistent with FDA-approved findings that continue to support that the use of VASCEPA has the potential to transform cardiovascular care in appropriate high-risk patients.
Slides from the presentation are available at http://www.scai.org/SCAI2020
About Amarin
Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarins lead product, VASCEPA (icosapent ethyl), is available by prescription in the United States, Canada, Lebanon and the United Arab Emirates. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in China, the European Union and the Middle East. For more information about Amarin, visit http://www.amarincorp.com.
About Cardiovascular Risk
The number of deaths in the United States attributed to cardiovascular disease continues to rise.1,2 There are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds), in the United States. Stroke rates are similar, accounting for 1 of every 19 U.S. deaths (approximately 1 every 40 seconds).3
Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patients risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35% but that still leaves a 65-75% risk remaining.4 People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.5,6,7
About REDUCE-IT
REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).
REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.8The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.9The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.10 These and other publications can be found in the R&D section on the companys website at http://www.amarincorp.com.
About VASCEPA (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was initially launched in the United States in 2013 based on the drugs initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over eight million times. VASCEPA is covered by most major medical insurance plans. The new, cardiovascular risk indication for VASCEPA was approved by the FDA in December 2019.
Indications and Limitation of Use
VASCEPA is indicated:
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
Key clinical effects of VASCEPA on major adverse cardiovascular events are included in the Clinical Studies section of the prescribing information for VASCEPA, as set forth below:
Effect of VASCEPA on Time to First Occurrence of Cardiovascular Events in Patients with Elevated Triglyceride levels and Other Risk Factors for Cardiovascular Disease in REDUCE-IT
n (%)
n (%)
(17.2)
(22.0)
(0.68, 0.83)
(11.2)
(14.8)
(0.65, 0.83)
(6.1)
(8.7)
(0.58, 0.81)
(5.3)
(7.8)
(0.55, 0.78)
(4.3)
(5.2)
(0.66, 0.98)
(2.6)
(3.8)
(0.53, 0.87)
(2.4)
(3.3)
(0.55, 0.93)
[2] Determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT http://WWW.VASCEPA.COM.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the potential impact of VASCEPA in various clinical uses. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with research and development and clinical trials such as further clinical evaluations failing to confirm earlier findings. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Amarins forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate.
Availability of Other Information About Amarin
Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarins investor relations website and may include social media channels. The contents of Amarins website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor and Media Inquiries:Elisabeth SchwartzInvestor RelationsAmarin Corporation plcIn U.S.: +1 (908) 719-1315investor.relations@amarincorp.com (investor inquiries)PR@amarincorp.com (media inquiries)
Lee M. SternSolebury TroutIn U.S.: +1 (646) 378-2992lstern@soleburytrout.com
_____________________________1 American Heart Association. Heart Disease and Stroke Statistics 2019 Update: A Report from the American Heart Association. Published January 31, 2019.2 American Heart Association / American Stroke Association. 2017. Cardiovascular disease: A costly burden for America projections through 2035.3 American Heart Association: Heart Disease and Stroke Statistics -- 2019 At-a-Glance.4 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.5 Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145.6 Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.7 Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563.8 Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCEIT: Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial. Clin Cardiol. 2017;40:138-148.9 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22.10 Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159-1161.
Go here to read the rest:
VASCEPA (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardiac Bypass Surgery, in...
- Bitfocus Buttons Enterprise Edition Unveiled at IBC2025 with Advanced Features - Digital Studio India - July 10th, 2025 [July 10th, 2025]
- Assembly Launches 'Assembly Control' to Elevate Brand Safety, Suitability, and Campaign Performance in Programmatic Media - Yahoo Finance - July 10th, 2025 [July 10th, 2025]
- Bluesky Gives Users More Control Over their Notifications - Social Media Today - July 8th, 2025 [July 8th, 2025]
- Spin Control: Media struggles after Trump swears with cameras rolling - The Spokesman-Review - July 8th, 2025 [July 8th, 2025]
- Beyond banks and brokers: All about decentralized finance (DeFi) - Britannica - July 8th, 2025 [July 8th, 2025]
- The Future of Crypto Payroll Security: Bitchat and Decentralized Messaging - OneSafe - July 8th, 2025 [July 8th, 2025]
- Paradigm leads $11.5 million funding round in Kuru Labs, a decentralized exchange blending CLOBs and AMMs - The Block - July 8th, 2025 [July 8th, 2025]
- Decentralized Payroll: The Future of Work - OneSafe - July 8th, 2025 [July 8th, 2025]
- Jack Dorsey tests Bitchat decentralized messaging without internet - Cointelegraph - July 8th, 2025 [July 8th, 2025]
- CrossFis Haley Cromer on Bridging Traditional Finance and Web3 for a Decentralized Future - BlockTelegraph - July 8th, 2025 [July 8th, 2025]
- India's Crypto Tax: Navigating New Norms with Decentralized Solutions - OneSafe - July 8th, 2025 [July 8th, 2025]
- Turkey Tightens Its Grip on Crypto: What It Means for Decentralized Exchanges - OneSafe - July 8th, 2025 [July 8th, 2025]
- Spheron and AIxBlock Unite to Democratize Decentralized AI - CoinTrust - July 8th, 2025 [July 8th, 2025]
- The Role of Web3 in Shaping NFT Marketplace Opportunities - Vocal - July 8th, 2025 [July 8th, 2025]
- BNB Adds Centralized Features, But Lightchain AI Adds Decentralized Incentives That Drive New Demand - Modern Diplomacy - July 8th, 2025 [July 8th, 2025]
- Taiko and Nethermind Partner to Enhance Ethereum Rollup Infrastructure - Blockchain News - July 8th, 2025 [July 8th, 2025]
- The Rise of Decentralized Stablecoins: Can They Replace Centralized Counterparts in 2025? - Vocal - July 8th, 2025 [July 8th, 2025]
- On MSNBC's Deadline: White House, Angelo Carusone highlights how Trump is losing control of narrative dominance due to "fractures" in... - July 8th, 2025 [July 8th, 2025]
- Assembly Control Transforms Programmatic Advertising with Revolutionary Brand Safety Platform - Stock Titan - July 4th, 2025 [July 4th, 2025]
- Now, United States Border Control Scrutinizes Social Media: For The Travelers To The United States from France, Spain, and Beyond, Here Is All You... - July 4th, 2025 [July 4th, 2025]
- Assembly Launches 'Assembly Control' to Elevate Brand Safety, Suitability, and Campaign Performance in Programmatic Media - Macau Business - July 4th, 2025 [July 4th, 2025]
- Breaking the Studio Social Media Blackout: Caylee Cowan Takes Creative Control and Financial Freedom with Fanfix - Silicon UK - June 28th, 2025 [June 28th, 2025]
- Aleema's control over PTI social media makes her all-powerful within Imran-founded party - Geo News - June 26th, 2025 [June 26th, 2025]
- Tuenti social media co-founder takes control of Puerto Bans bullring with plans to demolish it - Sur in English - June 20th, 2025 [June 20th, 2025]
- InMobi Advertising Unveils Mobile-First Curation Platform Empowering All Media Buyers with Precision, Transparency, and Control - Passionate In... - June 20th, 2025 [June 20th, 2025]
- Trump takes control of media cycle with travel ban, Harvard visa restriction, Biden investigation policy spree - Washington Examiner - June 7th, 2025 [June 7th, 2025]
- Pushed Out and Unfiltered: Joy Reid, Misogynoir, Media Control,and the Fear of a Black Womans Voice - Daily Kos - June 7th, 2025 [June 7th, 2025]
- GitGuardian urges shift to machine identity control - SC Media - May 11th, 2025 [May 11th, 2025]
- Opinion: Its time to lose control - Main Street Media of Tennessee - May 8th, 2025 [May 8th, 2025]
- Opinion | How a Professional Bully Is Winning Control of the Media - Common Dreams - April 30th, 2025 [April 30th, 2025]
- Social Media, Social Control, and the Politics of Public Shaming - - Political Science Now - April 21st, 2025 [April 21st, 2025]
- Tariff saga creates a meme war on social media, making it difficult for brands to 'control the message' - Digiday - April 21st, 2025 [April 21st, 2025]
- Conservatives are limiting media access to Poilievre. Is it helping or hurting him? - CBC - April 12th, 2025 [April 12th, 2025]
- Robert W. McChesney, who warned of corporate media control, dies at 72 - Editor and Publisher - April 10th, 2025 [April 10th, 2025]
- FCC Commissioner Anna Gomez Sounds Alarm Over Trump Administrations Absolute Pattern of Censorship and Control - Variety - April 10th, 2025 [April 10th, 2025]
- 'Attack lined up': Grenon says he offered compromise but believes NZME board has 'no interest' - NZ Herald - April 8th, 2025 [April 8th, 2025]
- Russia seeks full control of partially occupied Ukrainian regions in talks with US, media reports - Kyiv Independent - March 26th, 2025 [March 26th, 2025]
- Navigating the digital world without letting it control you. - Psychology Today - March 25th, 2025 [March 25th, 2025]
- ANZ Digital Padlock to give customers real-time control in fight against fraud and scams - ANZ - March 25th, 2025 [March 25th, 2025]
- Trump Handpicking Reporters and Bezos Partisan Shift: A Trend in Media Control - MSN - March 13th, 2025 [March 13th, 2025]
- Spains New Media Law Sparks Fears of Censorship and State Control - The European Conservative - March 5th, 2025 [March 5th, 2025]
- We dont feel we have control: How social media algorithms have warped our attention spans - MSNBC - March 3rd, 2025 [March 3rd, 2025]
- White House takes control of the press pool covering Trump - Reuters - March 3rd, 2025 [March 3rd, 2025]
- White House takes control of the press pool covering Trump - Reuters - March 3rd, 2025 [March 3rd, 2025]
- We dont feel we have control: How social media algorithms have warped our attention spans - MSNBC - March 3rd, 2025 [March 3rd, 2025]
- Reuters and Associated Press among outlets barred from Trumps first cabinet meeting - Semafor - March 3rd, 2025 [March 3rd, 2025]
- Reuters and Associated Press among outlets barred from Trumps first cabinet meeting - Semafor - March 3rd, 2025 [March 3rd, 2025]
- White House seizes control of press pool, will decide which outlets cover events with president - POLITICO - March 3rd, 2025 [March 3rd, 2025]
- White House seizes control of press pool, will decide which outlets cover events with president - POLITICO - March 3rd, 2025 [March 3rd, 2025]
- Epson And Show Sage At USITT 2025 Showcasing New 4K Projection With New Media Server And Control Tech - Live Design - March 3rd, 2025 [March 3rd, 2025]
- Epson And Show Sage At USITT 2025 Showcasing New 4K Projection With New Media Server And Control Tech - Live Design - March 3rd, 2025 [March 3rd, 2025]
- White House takes control of picking media who cover Trump - El Paso Inc. - March 3rd, 2025 [March 3rd, 2025]
- White House takes control of picking media who cover Trump - El Paso Inc. - March 3rd, 2025 [March 3rd, 2025]
- Trump administration to take control of media access at White House - New Straits Times - March 3rd, 2025 [March 3rd, 2025]
- USAID spent millions of dollars to promote media control through Internews which is linked to India based Factshala - Organiser - February 16th, 2025 [February 16th, 2025]
- Inaccurate reporting on foot and mouth disease controls - Defra in the media - February 16th, 2025 [February 16th, 2025]
- Russian forces take control of two settlements in eastern Ukraine, Media - APA - February 16th, 2025 [February 16th, 2025]
- TikTok's woes in the United States highlight the 'Godfather' battle to control social media - ABC News - February 5th, 2025 [February 5th, 2025]
- Jesse Watters: Air traffic control was "unable to meet their own DEI quotas, and thats what is leading to staffing shortages" - Media... - February 5th, 2025 [February 5th, 2025]
- Hive to launch Beeblade Nexus media control engine - Installation and AV Technology Europe - January 27th, 2025 [January 27th, 2025]
- Pakistan introduces law allowing government to block platforms, imprison users for spreading 'disinformat - The Times of India - January 27th, 2025 [January 27th, 2025]
- This little media control button is the gadget I can't live without - MSN - January 22nd, 2025 [January 22nd, 2025]
- Effective role of media is a must for tobacco control, experts say - bdnews24.com - January 22nd, 2025 [January 22nd, 2025]
- Effective media role vital for tobacco control: Experts - United News of Bangladesh - UNB - January 22nd, 2025 [January 22nd, 2025]
- How Government & Legacy Media CONTROL What We Think - iHeartRadio - January 9th, 2025 [January 9th, 2025]
- SNL kinda banned this 1998 'Schoolhouse Rock' parody warning about corporate media control - Upworthy - December 30th, 2024 [December 30th, 2024]
- Palestinian Authority: Jews Lied About Oct. 7 Because They Control the Media - Algemeiner - December 30th, 2024 [December 30th, 2024]
- NDCs control of major media houses gave them edge in 2024 polls Bawumia - Adomonline - December 22nd, 2024 [December 22nd, 2024]
- Hallmark Insights to Tackle the Debate on Social Media Management and Control in Organizations - PC Tech Magazine - December 14th, 2024 [December 14th, 2024]
- Rupert Murdochs bid to change familys trust over Fox News media empire control is rejected - Washington Times - December 10th, 2024 [December 10th, 2024]
- Rupert Murdoch loses battle to control succession to his media empire - The Guardian - December 10th, 2024 [December 10th, 2024]
- Journalist Abducted in Guinea Amid Military's Increasing Control Over Media - Oneindia - December 5th, 2024 [December 5th, 2024]
- Aleppo and Idlib Under Opposition Control, With Eyes on Hama - The Media Line - December 5th, 2024 [December 5th, 2024]
- Remilekun Dosumu takes the helm as Head of Media Buying & Control at PHD Nigeria - Marketing Edge - December 5th, 2024 [December 5th, 2024]
- Media reports US Republicans regaining control of House of Representatives - MENAFN.COM - November 14th, 2024 [November 14th, 2024]
- Social media misinformation is scaring women about birth control - STAT - November 5th, 2024 [November 5th, 2024]
- The (Lack Of) Science Behind Social Media Claims Of Weather Control - Forbes - October 14th, 2024 [October 14th, 2024]
- No, the government is not controlling the weather. "It's so stupid, it's got to stop," Biden says - CBS News - October 14th, 2024 [October 14th, 2024]
- Column: Media tries to control the narrative | Aiken Standard - The Post and Courier - October 12th, 2024 [October 12th, 2024]
- DoubleVerify To Introduce Pre-Screen Content Control On Meta, Strengthening Brand Safety, Suitability, Media Performance - Business - October 12th, 2024 [October 12th, 2024]